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Background
Screening for increased waist circumference and hyper-
triglyceridemia (the hypertriglyceridemic-waist pheno-
type) is an inexpensive approach to identify patients at
risk of coronary artery disease in apparently healthy
individuals who may be at increased risk of type 2 dia-
betes and coronary heart disease because of an excess of
intra-abdominal (visceral) fat. We examined the rela-
tionship between the hypertriglyceridemic-waist and
selected cardiometabolic risk factors in HIV individuals.
Methods
The HW phenotype was defined as a waist circumfer-
ence of 90 cm or more and a triglyceride level of 2.0
mmol/L or more in men, and a waist circumference of
85 cm or more and a triglyceride level of 1.5 mmol/L or
more in women. Using these threshold values a total of
2322 patients (841 women and 1481 men) with HIV
aged 18-75 years were divided into 4 groups: Low TG/
Low WC, High TG/Low WC, Low TG/High WC, High
TG/High WC. Continuous variables were analyzed
using ANOVA or Kruskal-Wallis test where appropriate;
categorical variables were compared using X2-test. The
relationship between the HW and cardiometabolic risk
assessed with Framingham risk score (FRS) was analyzed
using multivariable logistic regression analyses.
Results
Compared with patients who had a waist circumference
and triglyceride level below the threshold values, those
with the HW phenotype had higher visceral adipose tis-
sue (P<0.001), higher prevalence of hypertension and
the metabolic syndrome (P<0.001), higher levels of total
and LDL-cholesterol (P<0.001), lower levels of high-den-
sity lipoprotein cholesterol (P<0.001), and higher values
of HOMA-insulin resistance (P<0.001) as shown in
Table 1.
The FRS (median 10, range 5;16) was also highest in
those with the HW phenotype (P<0.001). These observa-
tions were true independent of gender and remained
significant after statistical control for illicit drug use,
insulin resistance, antiretroviral therapy exposure, leg
fat, and proteinuria as shown in image 1. Figure 1
Conclusions
Among HIV patients from an Italian monocentric
cohort, the HW phenotype was associated with a dete-
riorated cardiometabolic risk profile and an increased
FRS. It is suggested that the simultaneous measurement
and interpretation of waist circumference and fasting
triglyceride could also be used among HIV patients as
an inexpensive tool to identify patients with excess visc-
eral fat and with related cardiometabolic abnormalities.
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Low TG/Low WC High TG/Low WC Low TG/High WC High TG/High WC P value
n (%) 592 (25.50) 856 (36.86) 311 (13.39) 563 (24.25) -
DEMOGRAPHICS
Women, n (%) 284 (47.9) 245 (28.62) 145 (46.62) 167 (29.66) < 0.001
Age mean (± S) 43.3 (6.7) 44.4 (6.6) 45.4 (7.7) 46.9 (7.8) < 0.001
Physical activity, n (%) 232 (39.19) 282 (32.94) 103 (33.12) 152 (27.00) < 0.001
Smoke (> 10 cigs/day), n (%) 187 (31.59) 285 (33.29) 73 (23.47) 165 (29.31) 0.010
Alcohol consumption, n (%) 270 (45.61) 363 (42.41) 154 (49.52) 279 (49.56) 0.032
ANTHROPOMETRICS
BMI mean (± SD) 21.2 (2.2) 21.7 (2.3) 26.3 (3.9) 27.1 (3.8) < 0.001
VAT cm
3, median (IQR) 75 (49; 103) 100 (67; 138) 136 (101; 194) 172 (125; 236) < 0.001
Waist Circumference cm, median (IQR) 79 (75; 83) 81 (77; 85) 94 (90; 98) 95 (91; 101) < 0.001
Hip Circumference cm, median (IQR) 87 (83; 90) 86 (83; 89) 94 (91; 97) 94 (90.5; 98) < 0.001
Thigh Circumference cm, median (IQR) 45 (42.5; 48) 45 (43; 48) 49 (46; 52) 49 (46; 52) < 0.001
% of Leg Fat, median (IQR) 12.6 (7.2; 19.9) 7.7 (5.6; 12.7) 18.1 (12.5; 26.2) 14.0 (9.9; 21.1) < 0.001
HIV history
IDU n (%) 201 (33.95%) 286 (33.41%) 99 (31.83%) 151 (26.82%) < 0.001
CD4+ Nadir median (IQR) 181 (78; 260) 154 (59; 260) 189 (90; 290) 171.5 (63; 260) 0.014
CD4+ Current median (IQR) 499.5 (370; 672) 523 (364; 700) 492 (360; 658) 543.5 (375; 737) 0.113
VL undetectable n (%) 363 (61.32) 492 (57.48) 190 (61.09) 329 (58.44) 0.432
Months of PI exposure median (IQR) 24 (0; 60) 35.5 (8; 69.5) 30 (0; 58) 39 (9;7269) 0.005
Months of NNRTI exposure median (IQR) 16 (0; 45) 18 (0; 48) 17 (0; 49) 16 (0; 46) 0.445
CARDIOVASCULAR
Framingham risk median (IQR) 2 (1; 5) 6 (2; 10) 2 (1; 6) 6 (2; 12) < 0.001
Hypertension, n (%) 131 (22.13) 302 (35.28) 119 (38.26) 259 (46.00) < 0.001
Albuminuria, n (%) 38 (6.42) 84 (9.81) 24 (7.72) 59 (10.48) < 0.001
LIPID METABOLISM
Triglycerides median (IQR), mmol/L 1.03 (0.81; 1.27) 2.32 (1.87; 3.41) 1.10 (0.89; 1.30) 2.37 (1.85; 3.34) < 0.001
Total cholesterol mean (± SD), mmol/L 4.43 (1.09) 5.05 (1.22) 4.55 (1.10) 5.17 (1.30) < 0.001
HDL mean (± SD), mmol/L 1.36 (0.44) 1.05 (0.42) 1.33 (0.41) 1.06 (0.30) < 0.001
LDL mean (± SD), mmol/L 2.70 (0.84) 3.02 (1.03) 2.83 (0.91) 3.09 (1.01) < 0.001
ApoA1 mean (± SD), mg/dL 148.7 (32.6) 137.5 (26.8) 149.9 (29.8) 139.7 (27.0) < 0.001
ApoB mean (± SD), mg/dL 85.6 (23.4) 108.8 (29.0) 90.3 (24.3) 110.3 (27.3) < 0.001
HOMA-IR median (IQR) 2.25 (1.39; 3.38) 3.07 (2.04; 5.01) 3.26 (2.21; 5.13) 4.31 (2.74; 6.68) < 0.001
Figure 1 Univariate and multivariable logistic regression anlyses for associated factors with Framingham risk score more than 20%.
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